PDLIM2 expression is driven by vitamin D and is involved in the pro-adhesion, and anti-migration and -invasion activity of vitamin D

Oncogene

Volumn 33, Issue 15, 2014, Pages 1904-1911

  Vanoirbeek, E ^a   Eelen, G ^a   Verlinden, L ^a   Carmeliet, G ^a   Mathieu, C ^a   Bouillon, R ^a   O'connor, R ^b   Xiao, G ^c   Verstuyf, A ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

breast cancer; DNA methylation; metastasis; PDLIM2; vitamin D

Indexed keywords

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIM DOMAIN PROTEINS; MCF-7 CELLS; MICROFILAMENT PROTEINS; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CALCITRIOL; TRANSCRIPTIONAL ACTIVATION; VITAMIN D;

EID: 84899411750     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.123     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
2. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat Rev Cancer 2007; 7: 684-700
3. Verlinden L, Verstuyf A, Convents R, Marcelis S, Van Camp M, Bouillon R. Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol 1998; 142: 57-65
4. Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, et al. Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: A study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer 2010; 10: 483
5. Eelen G, Verlinden L, van Camp M, van Hummelen P, Marchal K, De Moor B, et al. The effects of 1alpha,25-dihydroxyvitamin D3 on the expression of DNA replication genes. J Bone Miner Res 2004; 19: 133-146
6. Eelen G, Gysemans C, Verlinden L, Vanoirbeek E, De Clercq P, Van Haver D, et al. Mechanism and potential of the growth-inhibitory actions of vitamin D and analogs. Curr Med Chem 2007; 14: 1893-1910
7. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28
8. Qu Z, Yan P, Fu J, Jiang J, Grusby MJ, Smithgall TE, et al. DNA methylationdependent repression of PDZ-LIM domain-containing protein 2 in colon cancer and its role as a potential therapeutic target. Cancer Res 2010; 70: 1766-1772
9. Loughran G, Healy NC, Kiely PA, Huigsloot M, Kedersha NL, O'Connor R. Mystique is a new insulin-like growth factor-I-regulated PDZ-LIM domain protein that promotes cell attachment and migration and suppresses anchorage-independent growth. Mol Biol Cell 2005; 16: 1811-1822
10. Qu Z, Fu J, Yan P, Hu J, Cheng SY, Xiao G. Epigenetic repression of PDZ-LIM domain-containing protein 2: Implications for the biology and treatment of breast cancer. J Biol Chem 2010; 285: 11786-11792
11. Torrado M, Senatorov VV, Trivedi R, Fariss RN, Tomarev SI. Pdlim2, a novel PDZ-LIM domain protein, interacts with alpha-Actinins and filamin A. Invest Ophthalmol Vis Sci 2004; 45: 3955-3963
12. Wei Q, Adelstein RS. Conditional expression of a truncated fragment of nonmuscle myosin II-A alters cell shape but not cytokinesis in HeLa cells. Mol Biol Cell 2000; 11: 3617-3627
13. Buss F, Luzio JP, Kendrick-Jones J. Myosin VI, an actin motor for membrane traffic and cell migration. Traffic 2002; 3: 851-858
14. Vanoirbeek E, Eelen G, Verlinden L, Marchal K, Engelen K, De Moor B, et al. Microarray analysis of MCF-7 breast cancer cells treated with 1,25-dihydroxyvitamin D3 or a 17-methyl-D-ring analog. Anticancer Res 2009; 29: 3585-3590
15. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, et al. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005; 19: 2685-2695
16. Chen KS, DeLuca HF. Cloning of the human 1 alpha,25-dihydroxyvitamin D3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim Biophys Acta 1995; 1263: 1-1269
17. Hsu JW, Yasmin-Karim S, King MR, Wojciechowski JC, Mickelsen D, Blair ML, et al. Suppression of prostate cancer cell rolling and adhesion to endothelium by 1alpha,25-dihydroxyvitamin D3. Am J Pathol 2011; 178: 872-880
18. Pálmer HG, González-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, et al. Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001; 154: 369-387
19. Zijlstra A, Lewis J, Degryse B, Stuhlmann H, Quigley JP. The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 2008; 13: 221-234
20. Liu W, Guo M, Ezzat S, Asa SL. Vitamin D inhibits CEACAM1 to promote insulin/ IGF-I receptor signaling without compromising anti-proliferative action. Lab Invest 2011; 91: 147-156
21. Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene 2006; 25: 6170-6175
22. Ishteiwy RA, Ward TM, Dykxhoorn DM, Burnstein KL. The microRNA-23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. PLoS One 2012; 7: E52106
23. Wang WL, Chatterjee N, Chittur SV, Welsh J, Tenniswood MP. Effects of 1a,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer 2011; 18: 10-58
24. Wang X, Gocek E, Liu CG, Studzinski GP. MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle 2009; 8: 736-741
25. Shah AK, Lazatin J, Sinha RK, Lennox T, Hickok NJ, Tuan RS. Mechanism of BMP-2 stimulated adhesion of osteoblastic cells to titanium alloy. Biol Cell 1999; 91: 131-142
26. Healy NC, O'Connor R. Sequestration of PDLIM2 in the cytoplasm of monocytic/ acrophage cells is associated with adhesion and increased nuclear activity of NF-kappaB. J Leukoc Biol 2009; 85: 481-490
27. Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, et al. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res 2010; 70: 5953-5962
28. Lopez-Serra L, Ballestar E, Fraga MF, Alaminos M, Setien F, Esteller M. A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer. Cancer Res 2006; 66: 8342-8346
29. Estecio MR, Issa JP. Dissecting DNA hypermethylation in cancer. FEBS Lett 2011; 585: 2078-2086
30. Doig CL, Singh PK, Dhiman VK, Thorne JL, Battaglia S, Sobolewski M, et al. Recruitment of NCOR1 to VDR target genes is enhanced in prostate cancer cells and associates with altered DNA methylation patterns. Carcinogenesis 2012; 34: 248-256
31. Cheng X, Blumenthal RM. Coordinated chromatin control: Structural and functional linkage of DNA and histone methylation. Biochemistry 2010; 49: 2999-3008
32. Pereira F, Barbáchano A, Singh PK, Campbell MJ, Muñoz A, Larriba MJ. Vitamin D has wide regulatory effects on histone demethylase genes. Cell Cycle 2012; 11: 1081-1089
33. Verstuyf A, Verlinden L, Van Baelen H, Sabbe K, D'Hallewyn C, De Clercq P, et al. The biological activity of nonsteroidal vitamin D hormone analogs lacking both the C-And D-rings. J Bone Miner Res 1998; 13: 549-558
34. Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, Marchal K, et al. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor/progesterone receptor/HER-2 breast carcinomas. Cancer Res 2007; 67: 6574-6581
35. Raemaekers T, Ribbeck K, Beaudouin J, Annaert W, Van Camp M, Stockmans I, et al. NuSAP, a novel microtubule-Associated protein involved in mitotic spindle organization. J Cell Biol 2003; 162: 1017-1029
36. Verlinden L, Eelen G, Beullens I, Van Camp M, Van Hummelen P, Engelen K, et al. Characterization of the condensin component Cnap1 and protein kinase Melk as novel E2F target genes down-regulated by 1,25-dihydroxyvitamin D3. J Biol Chem 2005; 280: 37319-37330